Infectious disease expert Fauci calls US vaccine rollout 'disappointing'

National Institute of Allergy and Infectious Diseases director Anthony Fauci on Thursday said that the coronavirus vaccine rollout hasn't gone as he expected adding that it has been 'disappointing'

Anthony Fauci
Dr. Anthony Fauci
ANI US
2 min read Last Updated : Jan 01 2021 | 7:52 AM IST

Don't want to miss the best from Business Standard?

National Institute of Allergy and Infectious Diseases director Anthony Fauci on Thursday said that the coronavirus vaccine rollout hasn't gone as he expected adding that it has been 'disappointing'.

"We would have liked to have seen it run smoothly and have 20 million doses into people today by the end of 2020, which was the projection," Fauci said during an appearance on "Today", as quoted by The Hill and added, "Obviously, it didn't happen, and that's disappointing."

The outgoing US President Donald Trump's administration had touted a goal of getting 20 million people the first dose of a COVID-19 vaccine by the end of the year but it was reported that the actual number will fall far short of that mark.

The Centers for Disease Control and Prevention's COVID data tracker stated that about 2.8 million people have received their first vaccine dose as of Thursday.

The US infectious diseases expert hopes that the vaccine distribution will increase in January but that local municipalities will need support in order for that to happen.

"There really has to be a lot more effort in the sense of resources for the locals, namely, the states, the cities, the counties, the places where the vaccine is actually going into the arms of individuals," he said.

Fauci continues to remain optimistic even though cases across the United States are rising and most recently a case of the newly strain of COVID was found in the US.

"The good news is that science has and will come to the rescue getting us vaccines," he said. "More than one vaccine, hopefully, five, six, seven or more vaccines throughout the world, that will get us out of this and put this in the rear-view mirror, behind us.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineUS

First Published: Jan 01 2021 | 7:40 AM IST

Next Story